Loading…
Loading…
EQUITY / NASDAQ · XNMS
Skye Bioscience Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.68 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.68 USD · Volume 11,138
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -11,061,303 USD | -18,243,925 USD | — |
| Net income | -10,786,594 USD | -17,624,872 USD | — |
| Cash and cash equivalents | 8,068,357 USD | — | — |
| Total liabilities | 11,531,102 USD | — | — |
| Total equity | -497,307 USD | 43,676,709 USD | -101.14% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 8,068,357 USD | — | — | 5,882,498 USD | 5,882,498 USD | 18,441,079 USD | — | — |
| Net incomeIncome statement | -10,786,594 USD | -23,295,955 USD | -12,509,361 USD | — | -55,924,814 USD | -12,754,660 USD | -41,482,851 USD | -17,624,872 USD |
| Operating profitIncome statement | -11,061,303 USD | -23,735,669 USD | — | — | -58,163,565 USD | -13,264,534 USD | -43,268,021 USD | -18,243,925 USD |
| Total assetsBalance sheet | 11,033,795 USD | — | — | 28,313,633 USD | 28,313,633 USD | 41,324,289 USD | — | — |
| Total equityBalance sheet | -497,307 USD | — | 9,011,804 USD | 20,024,175 USD | 20,024,175 USD | 32,836,185 USD | — | 43,676,709 USD |
| Total liabilitiesBalance sheet | 11,531,102 USD | — | — | 8,289,458 USD | 8,289,458 USD | 8,488,104 USD | — | — |
| Capital expendituresCash flow statement | — | 0 USD | — | — | 6,312 USD | — | 6,312 USD | — |
| Financing cash flowCash flow statement | — | -172,539 USD | — | — | 29,571 USD | — | 18,158 USD | — |
| Investing cash flowCash flow statement | — | 18,037,989 USD | — | — | -19,500,285 USD | — | -16,696,778 USD | — |
| Operating cash flowCash flow statement | — | -15,679,591 USD | — | — | -43,062,529 USD | — | -33,296,042 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/10/2026 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.